GLP-1 access guide
Are Mounjaro and Zepbound the same drug?
Mounjaro and Zepbound both contain tirzepatide and are Lilly brands, but they are different branded products with distinct approved labels. Mounjaro’s label concerns type 2 diabetes. Zepbound’s label includes weight reduction and maintenance and a specified obstructive-sleep-apnea indication. Their ingredient match does not make their prescriptions, pharmacy prices or savings programs interchangeable. [1][2]
At a glance
What the two products share
Both labels identify tirzepatide as a dual GIP and GLP-1 receptor agonist. The shared ingredient and classification are product-identification facts. They explain why the brands appear together in discussions of tirzepatide, but they do not establish one universal package or financial agreement. State the actual brand and presentation when you request a quote from a pharmacy or compare a provider’s offer. [1][2]
Lilly supplies the prescribing information and branded pharmacy-program material cited here. A telehealth company arranging care is a separate organization and can use its own clinical and billing process. The medicine’s manufacturer identity should not be confused with the identity of the service that evaluates the patient. The directory helps distinguish those roles; it does not issue prescriptions for either brand. [3][4][5]
Their approved indications are different
Mounjaro’s current prescribing information identifies its type 2 diabetes indication. Zepbound’s current information identifies weight reduction and maintenance and moderate-to-severe obstructive sleep apnea in a specified population with obesity. These summaries identify label categories rather than personal eligibility. The exact population, conditions and full requirements are in the applicable prescribing information. [1][2]
An ingredient match does not transfer an indication from one brand to another. This matters when a directory or advertisement calls every tirzepatide offer a weight-loss product without naming the finished drug. Ask which brand the care team proposes and which pharmacy process applies. We do not infer suitability or compare outcomes from the naming distinction. [6][1][2]
Presentation must stay with the brand
The current labels and pharmacy material describe different injection presentations. Zepbound’s information includes single-dose and multi-dose presentations, and its savings page applies different terms to particular packages. A brand-only heading can therefore be insufficient even after the ingredient is identified. The exact prescribed presentation is needed before comparing the pharmacy transaction. [2][4]
This guide does not translate quantities or provide instructions for replacing one presentation with another. A familiar ingredient or similar package name is not a substitute for the pharmacist’s identification of the actual prescription. The purpose of the table is to keep the brand, ingredient and label categories clear, leaving the clinical and dispensing decisions with the professionals responsible. [1][2]
Manufacturer offers are brand- and presentation-specific
LillyDirect publishes separate pharmacy information for Mounjaro and Zepbound. Those offers should not be treated as one tirzepatide cash price. Zepbound also has presentation- and strength-specific amounts and qualifying continuing-offer conditions. Use the dedicated price guide for the current transaction rather than applying the lowest starting amount to every package under both brands. [3][4]
The commercial-insurance savings cards likewise have different terms and caps. A qualifying as-little-as amount under one card is not a universal uninsured price or a benefit that follows the ingredient to another product. The savings-card guide provides the current dated distinctions. Confirm the actual card and pharmacy claim before using an example in a personal budget. [7][4]
A telehealth program can add another financial layer
A manufacturer pharmacy amount concerns medication; the prescribing service can bill care separately. A bundled compounded program uses a different arrangement again. Keep the medication price, care fee and commitment with the specific offer rather than ranking all tirzepatide references as identical all-in bills. Our membership guide explains those financial categories. [8][3][4]
Geographic coverage also belongs to the provider’s actual service and pharmacy arrangement. A company that serves a state for one medication category may not offer both brands or all presentations there. Use the relevant medication-state page and then obtain current confirmation for the prescription proposed after evaluation. A directory row does not guarantee an individual pharmacy fill. [5]
Compounded tirzepatide is another category
FDA distinguishes compounded preparations from approved finished drugs and approved generics. A preparation advertised as compounded tirzepatide does not become Mounjaro or Zepbound because a provider compares prices with those brands. The compounded formulation, source and applicable legal conditions need separate identification. Our compounded access guide preserves those limitations. [9][10][11]
When asking whether the two brands are the same, the precise answer is shared ingredient and manufacturer, distinct finished-product labels and transaction rules. Keep those dimensions separate in your notes. A clinician or pharmacist can then answer a product-specific question without a price advertisement or broad ingredient heading being mistaken for authorization to change a prescription. [1][2][6]
Additional reading from a provider
These pages describe a provider’s perspective or its own service. The official documents cited in this guide establish regulatory, approval and program facts.
- Gentle Health: Ozempic, Wegovy, Zepbound and Mounjaro overview (provider-authored)
Gentle’s brand overview discusses Mounjaro and Zepbound as distinct products; the Lilly labels above supply the authoritative identification.
Checked
Sources
Sources are checked on the dates shown. Official documents establish product and program rules; provider sources describe their own offers and the additional reading identified above. Provider catalog examples retain their original price-check dates; this article’s preparation date does not refresh them.
- Lilly: Mounjaro prescribing information — checked .
- Lilly: Zepbound prescribing information, August 2026 — checked .
- LillyDirect: Mounjaro self-pay prices — checked .
- LillyDirect: Zepbound pharmacy options and self-pay terms — checked .
- FDA BeSafeRx: online pharmacy questions — checked .
- FDA: development and approval process for drugs — checked .
- Lilly: Mounjaro savings card eligibility — checked .
- FTC: trials, automatic renewals and subscriptions — checked .
- FDA: compounding questions and answers — checked .
- FDA: generic drug facts and approval requirements — checked .
- FDA: compounding policies as GLP-1 supply stabilizes — checked .
- Gentle Health: Ozempic, Wegovy, Zepbound and Mounjaro overview (provider-authored) — checked .